J&J to share trial data via agreement with Yale

Johnson & Johnson (JNJ) has become the latest major pharmaceutical firm to say that it will make more data from its clinical trials available to researchers.

JNJ has signed an agreement with Yale University to share information about hundreds of drugs and other products.

Yale will vet requests from researchers without input from J&J.

Part of the idea is to increase the credibility of the data. "The medical scientific community and population at large want to have more transparency on what we do," says J&J's Paul Stoffels. "To get really credible, we took the leap."

Other big pharma companies to pledge to release data in the past year include GSK and Roche. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs